Phase 1/2 study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: overall safety at the recommended Phase 2 dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

Maria Alsina1, Andrea Varga2, Alessio Amatu3, Jan H.M. Schellens4, Els Witteveen5, Valentina Boni6, Victor Moreno7, Paolo Nuciforo1, Aurelia de Vries Schultink4, Kees Bol8, Afrodite Lourbakos8, Marina Magin Ferrer8, and Ernesto Wasserman8. 1Vall d’Hebron University Hospital, Barcelona, Spain; 2DITEP, Gustave Roussy, Villejuif, France; 3Niguarda Hospital, Milan, Italy; 4Netherlands Cancer Institute, Amsterdam, Netherlands; 5University Medical Center Utrecht, Netherlands; 6START CIOCC, Madrid, Spain; 7START – FJD, Madrid, Spain; 8Merus NV, Utrecht, Netherlands.

Poster presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany.